Drug ID:Drug179
Drug Name:Hemay005
CID:137355584
DrugBank ID:NULL
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT05486104
Molecular Formula:C20H22N2O7S2
Molecular Weight:466.5 g/mol
Isomeric SMILES:CCOC1=C(C=CC(=C1)[C@@H](CS(=O)(=O)C)N2C(=O)C3=CSC(=C3C2=O)NC(=O)C)OC
Synonyms:Mufemilast; Mufemilast [INN]; HEMAY005; 4QX9BK9E7P; 1255909-03-5; HEMAY-005; Acetamide, N-(5-((1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-5,6-dihydro-4,6-dioxo-4H-thieno(3,4-C)pyrrol-1-yl)-; (S)-N-(5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thiophene(3,4-c)pyrrol-1-yl)acetamide; UNII-4QX9BK9E7P; Mufemilast [WHO-DD]
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
No data available

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT05486104 Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Ganzhou Hemay Pharmaceutical Co., Ltd Moderate to Severe Ulcerative Colitis DRUG: Hemay005 tablets|DRUG: Hemay005 placebo tab… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

No related literature

You can run management commands to establish drug-literature associations